Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07543822 Alpelisib Vascular Malformations Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07543822 clinical trial report covering Alpelisib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07545603 Igermetostat Recurrent Follicular Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07545603 clinical trial report covering Igermetostat, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07543640 Roflumilast Psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07543640 clinical trial report covering Roflumilast, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07545083 Pucotenlimab Locally Advanced Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07545083 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07543783 Adebrelimab Unresectable Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07543783 clinical trial report covering Adebrelimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123143 Pucotenlimab Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600123143 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123189 Bevacizumab Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600123189 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07545772 Brenipatide Constipation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07545772 clinical trial report covering Brenipatide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07543848 Serplulimab Rectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07543848 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07545759 Brenipatide Irritable bowel syndrome with diarrhea Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07545759 clinical trial report covering Brenipatide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07545044 Anbenitamab repodatecan HER2 Positive Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07545044 clinical trial report covering Anbenitamab repodatecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07545746 Fluorouracil Cervical Intraepithelial Neoplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07545746 clinical trial report covering Fluorouracil, Phase 2, endpoints, sponsor, geography, readout timing and development white space.